Buspiron

Buspiron
(IUPAC) ime
	8-[4-(4-pirimidin-2-ilpiperazin-1-il)butil]-8-azaspiro[4.5]dekan-7,9-dion
Klinički podaci
Robne marke	Buspar
AHFS/Drugs.com	Monografija
MedlinePlus	a688005
Identifikatori
CAS broj	36505-84-7
ATC kod	N05BE01
PubChem	2477
DrugBank	DB00490
ChemSpider	2383
UNII	TK65WKS8HL
KEGG	D07593
ChEBI	CHEBI:3223
ChEMBL	CHEMBL49
Hemijski podaci
Formula	C21H31N5O2
Mol. masa	385,50314 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2 ; Key: QWCRAEMEVRGPNT-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	5%
Vezivanje za proteine plazme	95%
Metabolizam	Hepatic
Poluvreme eliminacije	2-3 sata
Izlučivanje	Urin (29-63%), izmet (18-38%)
Farmakoinformacioni podaci
Trudnoća	B(US)
Pravni status	℞ Prescription only
Način primene	Oralno

Buspiron (Buspar) je anksiolitički psihoaktivni lek iz azapironske hemijske klase. On se prvenstveno koristi za tretiranje generalizovanog anksioznog poremećaja.

Medicinska upotreba

Generalizovani anksiozni poremećaj blagog do umerenog intenziteta.^[6]
Studije su pokazale da je buspiron efektivan kao pojačavajući agens selektivnih inhibitora preuzimanja serotonina (SSRI) u lečenju depresije. Lek nije odobren za ovu vrstu primene.^[7]^[8]^[9]

Hemija

Sinteza buspirona počinje sa N-alkilacijom 1-(2-pirimidil)piperazina sa 4-hlorobutironitrilom čemu sledi hidrogenacija nitrila preko Ranejev nikal katalizatora. Primarni aminski produkt prethodnog koraka sa spirocikličnim kiselim anhidridom daje buspiron.^[10]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ „Buspirone monograph”. Drugs.com. Pristupljeno 27. 8. 2011.
↑ National Institute Of Health. „Questions and Answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study — All Medication Levels”. Arhivirano iz originala na datum 2012-08-19. Pristupljeno 12. 8. 2012.
↑ Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (March 2006). „Medication augmentation after the failure of SSRIs for depression”. N. Engl. J. Med. 354 (12): 1243–52. DOI:10.1056/NEJMoa052964. PMID 16554526.
↑ Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors and in a Class of Drugs called Benzodiazepines and effects similar if not idenical to Alprazelam,Lorazepam etc : results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. J Clin Psychiatry 62 (6): 448–52. PMID 11465522.
↑ Wu YH, Rayburn JW, Allen LE, Ferguson HC, Kissel JW (May 1972). „Psychosedative agents. 2. 8-(4-Substituted 1-piperazinylalkyl)-8-azaspiro(4.5)decane-7,9-diones”. J. Med. Chem. 15 (5): 477–9. DOI:10.1021/jm00275a009. PMID 5035267. ;
DE 2057845, Šablon:Cite patent/authors, "Heterocyclische Azaspirodecandione und Verfahren zu ihrer Herstellung", published 9. 6. 1971. ;
US 3717634, Šablon:Cite patent/authors, "N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones", published 20. 2. 1973. ;
US 3907801, Šablon:Cite patent/authors, "N8 (4-pyridyl-piperazino)-alkyl9-azaspiroalkanediones", published 23. 9. 1975. ;
US 3976776, Šablon:Cite patent/authors, "Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones", published 24. 8. 1976.

Vidi još

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[mono-6] „Buspirone monograph”. Drugs.com. Pristupljeno 27. 8. 2011.

[7] National Institute Of Health. „Questions and Answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study — All Medication Levels”. Arhivirano iz originala na datum 2012-08-19. Pristupljeno 12. 8. 2012.

[pmid16554526-8] Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (March 2006). „Medication augmentation after the failure of SSRIs for depression”. N. Engl. J. Med. 354 (12): 1243–52. DOI:10.1056/NEJMoa052964. PMID 16554526.

[pmid11465522-9] Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors and in a Class of Drugs called Benzodiazepines and effects similar if not idenical to Alprazelam,Lorazepam etc : results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. J Clin Psychiatry 62 (6): 448–52. PMID 11465522.

[10] Wu YH, Rayburn JW, Allen LE, Ferguson HC, Kissel JW (May 1972). „Psychosedative agents. 2. 8-(4-Substituted 1-piperazinylalkyl)-8-azaspiro(4.5)decane-7,9-diones”. J. Med. Chem. 15 (5): 477–9. DOI:10.1021/jm00275a009. PMID 5035267. ;
DE 2057845, Šablon:Cite patent/authors, "Heterocyclische Azaspirodecandione und Verfahren zu ihrer Herstellung", published 9. 6. 1971. ;
US 3717634, Šablon:Cite patent/authors, "N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones", published 20. 2. 1973. ;
US 3907801, Šablon:Cite patent/authors, "N8 (4-pyridyl-piperazino)-alkyl9-azaspiroalkanediones", published 23. 9. 1975. ;
US 3976776, Šablon:Cite patent/authors, "Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones", published 24. 8. 1976.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]